Loading...
At this year's annual meeting of the American Society of Clinical Oncology (ASCO 2018), held June 1–5 in Chicago, investigators discussed the latest findings in cancer research. The editors of NEJM Journal Watch Oncology and Hematology were on hand to report highlights of the conference. Here, Associate Editor Robert Dreicer, MD, MS, FACP, FASCO, reviews key presentations on new genitourinary cancer therapies. All meeting abstracts can be viewed in the ASCO meeting library.
Combination therapy with the anti-PD-1 checkpoint inhibitor nivolumab and the anti-CTLA-4 agent ipilimumab was recently shown to significantly improve survival in in patients with intermediate or poor-risk metastat…